1.08
Schlusskurs vom Vortag:
$1.08
Offen:
$1.07
24-Stunden-Volumen:
952.12K
Relative Volume:
1.35
Marktkapitalisierung:
$108.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.65M
KGV:
-3.252
EPS:
-0.3321
Netto-Cashflow:
$-15.84M
1W Leistung:
+14.38%
1M Leistung:
+2.86%
6M Leistung:
-25.52%
1J Leistung:
-25.52%
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Vergleichen Sie CRDL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
CRDL
Cardiol Therapeutics Inc
|
1.08 | 108.00M | 0 | -21.65M | -15.84M | -0.3321 |
|
ZTS
Zoetis Inc
|
118.07 | 51.01B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.37 | 45.05B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.46 | 41.46B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.80 | 32.77B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
484.86 | 20.51B | 3.08B | 1.24B | 1.07B | 25.61 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-26 | Eingeleitet | ROTH MKM | Buy |
| 2024-04-22 | Eingeleitet | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Aktie (CRDL) Neueste Nachrichten
Investors in cash trouble should check out Cardiol Therapeutics Inc (CRDL) - Setenews
Inflation Data: Will Cardiol Therapeutics Inc CT9 stock outperform small cap peersMarket Activity Report & Fast Entry Momentum Alerts - BỘ NỘI VỤ
(CRDL) Investment Analysis and Advice (CRDL:CA) - news.stocktradersdaily.com
Is Cardiol Therapeutics Inc. stock a defensive play in 2025July 2025 Analyst Calls & Safe Entry Point Alerts - Newser
Cardiol Therapeutics Reports Q3 2025 Financial Results Amidst Cash Decrease - MSN
(CRDL) Market Dynamics and Trading Signals (CRDL:CA) - news.stocktradersdaily.com
How buyback programs support Cardiol Therapeutics Inc. (CT9) stockAnalyst Upgrade & Proven Capital Preservation Tips - Newser
Why institutional investors increase stakes in Cardiol Therapeutics Inc. (CT9) stock2025 Retail Activity & Free Real-Time Market Sentiment Alerts - Newser
Should you sell your Cardiol Therapeutics stock? - Cantech Letter
Is Cardiol Therapeutics Inc. stock attractive for passive investorsMarket Performance Summary & Consistent Growth Stock Picks - Newser
Will Cardiol Therapeutics Inc. (CT9) stock announce special dividendWeekly Profit Recap & Daily Volume Surge Signals - Newser
Will Cardiol Therapeutics Inc. (CT9) stock issue positive guidanceJuly 2025 Action & Risk Controlled Swing Trade Alerts - Newser
What hedge fund moves indicate for Cardiol Therapeutics Inc. (CT9) stockMarket Movement Recap & Safe Entry Zone Identification - Newser
Will Cardiol Therapeutics Inc. stock deliver consistent dividendsJuly 2025 Catalysts & Risk Adjusted Buy/Sell Alerts - Newser
What RSI levels show for Cardiol Therapeutics Inc. (CT9) stock2025 Trading Recap & Consistent Growth Stock Picks - Newser
Taking the lead: Cardiol Therapeutics Inc (CRDL) - Setenews
Cardiol Therapeutics (TSE:CRDL) Stock Price Down 14.6%Should You Sell? - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Trading Down 14.6%Should You Sell? - MarketBeat
Will Cardiol Therapeutics Inc. (CT9) stock recover faster than industryJuly 2025 PreEarnings & Verified Momentum Stock Watchlist - Newser
Cardiol Therapeutics (TSE:CRDL) Shares Down 14.6%Here's What Happened - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Shares Down 17.2%Here's What Happened - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Shares Down 13.9%What's Next? - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Trading Down 17.2%Here's What Happened - MarketBeat
Cardiol Therapeutics (NASDAQ:CRDL) Receives "Buy" Rating from HC Wainwright - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Trading Down 7.9%Here's Why - MarketBeat
H.C. Wainwright reaffirms Buy rating on Cardiol Therapeutics stock at $9 target - Investing.com Nigeria
H.C. Wainwright reaffirms Buy rating on Cardiol Therapeutics stock at $9 target By Investing.com - Investing.com South Africa
Is Cardiol Therapeutics Inc. (CT9) stock a top dividend aristocrat candidateGold Moves & Short-Term Trading Alerts - Newser
Why Cardiol Therapeutics Inc. stock appeals to analystsTrade Volume Report & Safe Entry Zone Identification - Newser
Cardiol Therapeutics’ (CRDL) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
HC Wainwright & Co. Reiterates Cardiol Therapeutics (CRDL) Buy Recommendation - Nasdaq
CRDL.NE Interactive Stock Chart | CARDIOL THERAPEUTICS INC Stock - Yahoo! Finance Canada
Cardiol Therapeutics (CRDL): HC Wainwright & Co. Reiterates Buy Rating | CRDL Stock News - GuruFocus
CRDL Analyst Forecasts - Quiver Quantitative
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions - TipRanks
Cardiol Therapeutics reports positive Phase II myocarditis trial results By Investing.com - Investing.com Nigeria
Cardiol Therapeutics Reports Positive Phase II ARCHER Trial Results for CardiolRx™ - TipRanks
CARDIOL THERAPEUTICS INC (CRDL.NE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cardiol Therapeutics reports positive Phase II myocarditis trial results - Investing.com
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions - Investing News Network
Cardiol Therapeutics (NASDAQ: CRDL) posts Phase II ARCHER myocarditis recovery data - Stock Titan
(CRDL) Stock Analysis and Trading Signals (CRDL:CA) - news.stocktradersdaily.com
What is Cardiol Therapeutics Inc (CRDL) Stock Return on Shareholders’ Capital? - Setenews
European Society of Cardiology Working Group on Myocardial and Pericardial Diseases Meeting - marketscreener.com
Finanzdaten der Cardiol Therapeutics Inc-Aktie (CRDL)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):